Bausch + Lomb, a Canadian eye health company based in Ontario, has announced significant progress in the development of a novel oral treatment for dry age-related macular degeneration (AMD) after a constructive meeting with the U.S. Food and Drug Administration (FDA).
The meeting, which took place recently, provided Bausch + Lomb with valuable insights into the regulatory pathway for its treatment. The company stated that the discussions were productive and helped clarify the requirements for advancing its clinical program.
Dry AMD is a leading cause of vision loss in older adults, and there is currently no approved treatment available. Bausch + Lomb’s oral therapy aims to address this unmet medical need by potentially slowing the progression of the disease.
“We are encouraged by the feedback received from the FDA, which will help guide our next steps in the development of this important treatment,” said a spokesperson for Bausch + Lomb. The company is now focused on finalizing its clinical trial design and preparing for the next phases of development.
The FDA’s engagement is seen as a positive step for Bausch + Lomb, which has been working on this treatment for several years. The company has emphasized its commitment to bringing innovative solutions to patients suffering from eye diseases.
As part of its ongoing efforts, Bausch + Lomb is also exploring other therapeutic options for eye health, aiming to expand its portfolio and address various conditions that affect vision.
With the prevalence of dry AMD increasing, the need for effective treatments is more pressing than ever. According to recent estimates, millions of Canadians are affected by age-related macular degeneration, underscoring the importance of research and development in this area.
Bausch + Lomb’s advancements in this field reflect a broader trend in the pharmaceutical industry, where companies are increasingly focused on developing targeted therapies for chronic conditions. The company’s commitment to innovation and patient care continues to position it as a leader in the eye health sector.